{
  "trial_id": "NCT00216060",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Histologically or cytologically confirmed adenocarcinoma of the prostate",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "metastatic bone disease (by CT, MRI or bone scan) with plans to start or be < 30 days from beginning androgen deprivation therapy",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "No neuroendocrine, small cell or transitional cell cancer of the prostate",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "No abnormal bone metabolism (i.e., Paget's disease, untreated hyperthyroidism, untreated hyperprolactinemia, untreated Cushing's disease)",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT00216060",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}